Last updated on February 2018

Autoreactive Anti-Ro/SSA IgE To Determine Primary Sj gRen's Syndrome's Disease Activity


Brief description of study

Primary Sjgren's syndrome (pSS) can affect various organs, sometimes leads to life-threatening conditions and is always responsible for a decreased quality of life. Its evolution is chronic, with flares and relapses, and the need for reliable biomarkers to be carried out routinely is major in patients' follow-up. Because of the existence of autoreactive immunoglobulins E (IgE) in autoimmune diseases, the recently described role for anti-Ro/SSA antibodies in inducing interferon alpha (IFN) signaling and the specific pharmacologic properties of IgE, anti-Ro/SSA IgE should be an interesting biomarker to determine pSS's activity. The aim of the study is to evaluate whether the proportion of anti-Ro/SSA IgE positive patients is higher in patients with active disease (i.e. Eular Sjgren Syndrome Disease Activity Index 5). All consecutive patients with pSS (new or already known diagnosis) will be included, Anti-Ro/SSA IgE titers will be determined, the disease's features will be collected (including Eular Sjgren Syndrome Disease Activity Index/Eular Sjogren's Syndrome Patient Reported Index).

Clinical Study Identifier: NCT03003572

Contact Investigators or Research Sites near you

Start Over

Marielle ROUX, MD

CH Pierre Oudot
Bourgoin-Jallieu, France
  Connect »